Name
*
First Name
Last Name
Email
*
example@example.com
Degree(s)
*
Institution
1. What are some red flags that, if present, should lead to the consideration of a diagnosis other than MS?
*
a. Negative oligoclonal bands
b. Severe positional vertigo
c. Asymptomatic T2 hyperintense ovoid brain lesion
d. Short segment spinal cord lesion
e. Both a and b
f. Both a and d
2. Which of the following statements is false regarding MS diagnosis:
*
a. In the 2024 MS diagnostic criteria revisions, kFLC can now be used in lieu of CSF-specific OCBs.
b. In the 2024 MS diagnostic criteria revisions, the central vein sign is essential for MS diagnosis.
c. In the 2024 MS diagnostic criteria revisions, people with RIS or presenting with atypical symptoms can receive a diagnosis of MS if they meet certain requirements.
d. In the 2024 MS diagnostic criteria revisions, paramagnetic rim lesions can be used in specific situations to facilitate a diagnosis of MS.
e. The CVS and PRLs are highly specific imaging biomarkers for MS diagnosis.
3. Which MS disease modifying therapy has been associated with autoimmune hepatitis?
*
a. Ofatumumab
b. Natalizumab
c. Ozanimod
d. Cladribine
e. Dimethyl fumarate
4. Which DMT is administrated subcutaneously?
*
a. Natalizumab
b. Dimethyl fumarate
c. Teriflunomide
d. Ocrelizumab and hyaluronidase
5. Why is CD19 CAR T being explored in multiple sclerosis?
*
a. B-cell depletion with anti-CD20 mAbs has been highly effective in relapsing MS and somewhat effective in progressive disease, though long-term B-cell depletion can lead to infectious complications.
b. Oligoclonal bands are persistent despite peripheral B-cell depletions, suggesting that the mAbs don't cross the blood brain barrier in significant quantities.
c. Engaging CD19 will more fully deplete the B-cell lineage because it is expressed on a broader population of B lymphocytes, including mature plasma cells.
d. Early successes in systemic autoimmune disorders has been well tolerated.
e. All of the above
Advance to Stream
Should be Empty: